Logo
Print this page

Cuba develops new Sovereign 01 A vaccine candidate, an added bonus to fight Covid-19

Featured Cuba develops new Sovereign 01 A vaccine candidate, an added bonus to fight Covid-19
Havana, Mar 5 - Cuba is not waiting on the beneficience of US President Joe Biden to ease the crushing  economic sanctions to determine whether it will be able to access Covid-19 vaccines. Its Development of four vaccine candidates against Covid-19 in a short time is a feat of Cuba's biotechnology, but reaching a fifth is an added bonus to the Cuban population.
Soberana 01 A - currently called Soberana Plus - is the product selected to boost a pre-existing immune response, that is, to reinforce antibody titers in patients exposed to the virus or vaccinated with other candidates.

soberana2 400In statements to Prensa Latina, Research Director at the Finlay Vaccine Institute (IFV) Dagmar Garcia pointed out that this product was part of the five formulations corresponding to Soberana 01, first presented by Cuba to face the pandemic.

With Soberana Plus, a study was carried out in convalescent Covid-19 patients between 19 and 59, who had mild symptoms or were asymptomatic for Covid-19 but had tested positive.

The study showed the ability of the molecule to stimulate protective levels of neutralizing antibodies and protect patients against possible reinfection.

Given these results, IFV Director Vicente Verez stressed that this step is essential in the protection against Covid-19, and when the mass vaccination stage is reached, it will help to face SARS-CoV-2 variants, mutations and strains.

In the meantime, Cuba's  Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) has authorized the initiation of phase III clinical trials of the Soberana 02 candidate vaccine, after a rigorous analysis of the documentation submitted by the Finlay Vaccine Institute on findings gathered thus far.

President of the Republic of Cuba Miguel Díaz-Canel Bermúdez yesterday also posted a tweet noting that phase III clinical trials were at hand for Soberana 02 and Abdala, in Havana, Santiago de Cuba and Guantánamo, with more than 85,000 volunteers; as well as phase II trials of Soberana 01 in Cienfuegos. "Welcome hope, but let us not forget responsibility," he added.

He also highlighted "another milestone of our science: Soberana 01A, a new candidate vaccine (Cuba's fifth) for recovering COVID-19 patients. Cuban science continues to report good news."

After producing what is the first vaccine in Latin America against the SARS-COV-2 virus, according to the Pan American Health Organization and the United Nations Industrial Development Organization, Cuba will be in an ideal position to launch a vaccination campaign to protect its people from COVID-19.

Following the production of the first batch of 150,000 doses of Soberana 02 (of the 100 million projected) and the preparation of the second batch, it was announced that production of the candidate vaccine Abdala has also begun.

-30-



rly/mem/cdg
Last modified onSaturday, 06 March 2021 06:31
  • Countries: Cuba
Design © by Studio6683 International Ltd.. All Rights Reserved.